Overview

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Determine Phase 2 dose of study drug
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Western Regional Medical Center
Treatments:
Antibodies, Monoclonal
Camptothecin
Capecitabine
Everolimus
Irinotecan
Nivolumab
Sirolimus